pembrolizumab (Alvotech)

AVT33 is a biosimilar candidate for **Keytruda** (pembrolizumab), a humanized monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. Developed by **Alvotech**, AVT33 is designed to inhibit the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby restoring the immune system's ability to recognize and eliminate tumor cells. In 2022, Alvotech expanded its strategic partnership with **JAMP Pharma** to include the exclusive commercialization of AVT33 in Canada, where JAMP Pharma is responsible for regulatory approval and marketing while Alvotech handles development and manufacturing. The program aims to provide a high-quality, more affordable alternative to the reference product for various oncology indications.

Other names

pembrolizumab biosimilarAlvotech pembrolizumab biosimilar